TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 7, Pages e004991
Publisher
BMJ
Online
2022-07-11
DOI
10.1136/jitc-2022-004991
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate
- (2022) Rosemina Merchant et al. Journal for ImmunoTherapy of Cancer
- Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression
- (2022) Christopher J. Nirschl et al. Cancer Immunology Research
- Function of γδ T cells in tumor immunology and their application to cancer therapy
- (2021) Jang Hyun Park et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- MDNA11 is a long-acting IL-2 superkine that potentiates durable immune response in mouse tumor models and non-human primates.
- (2021) Minh D. To et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys
- (2021) Jared E. Lopes et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
- (2021) Jerod L. Ptacin et al. Nature Communications
- Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans
- (2021) Nidhi Sharda et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- 16 Tumor growth inhibition mediated by a single dose of intratumoral TransCon™ TLR7/8 agonist was associated with activated circulating T and B cells and sustained low levels of systemic cytokines
- (2021) Amer Mirza et al. Journal for ImmunoTherapy of Cancer
- 769 A single dose of intratumoral TransCon™ TLR7/8 agonist monotherapy promoted sustained activation of antigen presenting cells resulting in CD4+ and CD8+ T cell activation and tumor growth inhibition
- (2021) Luis Zuniga et al. Journal for ImmunoTherapy of Cancer
- Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
- (2020) Wenyan Zhong et al. BMC GENOMICS
- ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
- (2020) Jared E Lopes et al. Journal for ImmunoTherapy of Cancer
- 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)
- (2020) U.N. Vaishampayan et al. ANNALS OF ONCOLOGY
- Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
- (2019) Zsolt Sebestyen et al. NATURE REVIEWS DRUG DISCOVERY
- IL-2 and Beyond in Cancer Immunotherapy
- (2018) John M. Wrangle et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
- (2017) Christian Klein et al. OncoImmunology
- The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency
- (2017) Kennett Sprogøe et al. Endocrine Connections
- Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
- (2017) Deborah Charych et al. PLoS One
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy
- (2014) F. Van Gool et al. BLOOD
- The IL-2 cytokine family in cancer immunotherapy
- (2014) Geok Choo Sim et al. CYTOKINE & GROWTH FACTOR REVIEWS
- The immune synapse clears and excludes molecules above a size threshold
- (2014) Adam N. R. Cartwright et al. Nature Communications
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
- (2013) Geok Choo Sim et al. JOURNAL OF CLINICAL INVESTIGATION
- Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
- (2013) T. Carmenate et al. JOURNAL OF IMMUNOLOGY
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
- (2010) C. Krieg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now